Geron
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Geron and other ETFs, options, and stocks.About GERN
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies.
GERN Key Statistics
Stock Snapshot
The current Geron(GERN) stock price is $1.07, with a market capitalization of 682.68M. The stock trades at a price-to-earnings (P/E) ratio of -8.99.
On 2025-11-07, Geron(GERN) stock moved within a range of $1.04 to $1.09. With shares now at $1.07, the stock is trading +2.9% above its intraday low and -1.8% below the session's peak.
Trading volume for Geron(GERN) stock has reached 4.27M, versus its average volume of 8.45M.
Over the past 52 weeks, Geron(GERN) stock has traded between a high of $4.50 and a low of $1.04.
Over the past 52 weeks, Geron(GERN) stock has traded between a high of $4.50 and a low of $1.04.
GERN News
Geron Corporation ( (GERN) ) has released its Q3 earnings. Here is a breakdown of the information Geron Corporation presented to its investors. Elevate Your In...
Geron (GERN) is set to outpace the broader US market with analysts forecasting revenue growth of 39.2% per year compared to the market’s 10.5% annual rate. Whil...
Geron Corporation ((GERN)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRan...
Analyst ratings
75%
of 8 ratingsMore GERN News
Earnings Call Insights Geron signals 2026 growth focus as RYTELO new patient starts rise to 36% in Q3 Nov. 05, 2025 2:21 PM ET Geron Corporation (GERN) Stock, G...
Geron, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a...
Reports Q3 revenue $47.23M, consensus $53.34M. “The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action an...